Changchun Hi-Tech announced that the recombinant human anti-respiratory syncytial virus monoclonal antibody injection combination developed by its subsidiary Baike Biotech to prevent lower respiratory infections caused by RSV in newborns and infants recently received a “Notice of Acceptance” from the State Drug Administration. The registration clinical trial application for domestically produced drugs was accepted. The acceptance number is CXSL2601038.

Changchun Hi-Tech announced that the recombinant human anti-respiratory syncytial virus monoclonal antibody injection combination developed by its subsidiary Baike Biotech to prevent lower respiratory infections caused by RSV in newborns and infants recently received a “Notice of Acceptance” from the State Drug Administration. The registration clinical trial application for domestically produced drugs was accepted. The acceptance number is CXSL2601038.